Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Clin Mol Hepatol. 2021;27(4):575-588.   Published online 2021 Jul 13     DOI: https://doi.org/10.3350/cmh.2021.0155
Citations to this article as recorded by Crossref logo
Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response
Chen‐Hua Liu, Chun‐Jen Liu, Tung‐Hung Su, Tai‐Chung Tseng, Pei‐Jer Chen, Jia‐Horng Kao
Advances in Digestive Medicine.2022;[Epub]     CrossRef
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus–related cirrhosis
Chen-Hua Liu, Chun-Jen Liu, Jia-Horng Kao
Journal of the Chinese Medical Association.2022; 85(5): 647.     CrossRef